A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)

被引:31
|
作者
Simojoki, Kaarlo [2 ]
Vorma, Helena [3 ]
Alho, Hannu [1 ,4 ]
机构
[1] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland
[2] A Clin Fdn, Espoo Treatment & Rehabil Ctr, Espoo, Finland
[3] Univ Helsinki, Dept Psychiat, Cent Hosp, SF-00180 Helsinki, Finland
[4] Univ Helsinki, Unit Subst Abuse Med, Helsinki, Finland
关键词
D O I
10.1186/1747-597X-3-16
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: In Finland, buprenorphine (Subutex) is the most abused opioid. In order to curb this problem, many treatment centres transferred ("forced transfer") their buprenorphine patients to the buprenorphine plus naloxone (Suboxone) combination product in late 2003. Methods: Data from a retrospective study involving five different treatment centers, examining the effects of switching patients to Suboxone, were gathered from 64 opioid-dependent patients who had undergone the medication transfer. Results: Most patients (90.6%) switched to Suboxone at the same dose of buprenorphine that they had been receiving as Subutex (average 22 mg). The majority of these patients (71.9%) were maintained at the same dose of Suboxone throughout the 4-week study period. During the first 4 weeks, 50% of the patients reported adverse events and at the four month time point, 26.6% reported adverse events. However, due to adverse events one patient only discontinued treatment with Suboxone during the 4-week study period, and five during the four month follow-up period. Of the 26 patients in the follow-up period, Suboxone was misused intravenously once each by 4 patients and twice by 1 patient. These 5 patients all reported that injecting Suboxone was like injecting "nothing" with any euphoria, or that it was a bad experience. Conclusion: We conclude that when patients are transferred from high doses (> 22 mg) of buprenorphine to the combination product, dose adjustments may be necessary especially in the later phase of the treatment. We recommend that a transfer from Subutex to Suboxone should be carefully discussed and planned in advance with the patients and after the transfer adverse events should be regularly monitored. With regard of buprenorphine IV abuse, the combination product seems to have a less abuse potential than buprenorphine alone.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
    Kaarlo Simojoki
    Helena Vorma
    Hannu Alho
    [J]. Substance Abuse Treatment, Prevention, and Policy, 3
  • [2] Preferences for Buprenorphine/Naloxone (Suboxone®) and Buprenorphine (Subutex®) in Patients Receiving Buprenorphine Maintenance Therapy in France: A Prospective, Multicentre Study
    Daulouede, Jean-Pierre
    Caer, Yves
    Galland, Pascal
    Villeger, Pierre
    Brunelle, Emmanuel
    Bachellier, Jerome
    Piquet, Jean-Michel
    Harbonnier, Jean
    Leglise, Yves
    Courty, Pascal
    [J]. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2009, 11 (01) : 41 - 42
  • [3] Buprenorphine/Naloxone (Suboxone) Fatality in a Child
    Kim, H. K.
    Hoffman, R. S.
    Nelson, L. S.
    [J]. CLINICAL TOXICOLOGY, 2012, 50 (04) : 343 - 343
  • [4] The Use of Suboxone (Buprenorphine and Naloxone) in Prison
    Meroueh, F.
    [J]. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2018, 20 : 70 - 70
  • [5] NON-BUPRENORPHINE OPIOID UTILIZATION AMONG PATIENTS USING BUPRENORPHINE/NALOXONE (SUBOXONE)
    Daubresse, Matthew
    Saloner, Brendan
    Pollack, Harold
    Alexander, G. Caleb
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S254 - S254
  • [6] NON-BUPRENORPHINE OPIOID UTILIZATION AMONG PATIENTS USING BUPRENORPHINE/NALOXONE (SUBOXONE)
    Daubresse, M.
    Saloner, B.
    Pollack, H.
    Alexander, G. C.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A302 - A303
  • [7] Budgetary impact analysis of buprenorphine-naloxone combination (suboxone®) in Spain
    Martinez-Raga J.
    Gonzalez-Saiz F.
    Oñate J.
    Oyagüez I.
    Sabater E.
    Casado M.A.
    [J]. Health Economics Review, 2 (1) : 1 - 9
  • [8] Suboxone (buprenorphine/naloxone) toxicity in pediatric patients - A case report
    Schwarz, Kerry A.
    Cantrell, F. Lee
    Clark, Richard F.
    Vohra, Rais B.
    [J]. PEDIATRIC EMERGENCY CARE, 2007, 23 (09) : 651 - 652
  • [9] Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration
    Canestrelli, Corinne
    Marie, Nicolas
    Noble, Florence
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 (09): : 1367 - 1373
  • [10] A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence
    Bell, J
    Byron, G
    Gibson, A
    Morris, A
    [J]. DRUG AND ALCOHOL REVIEW, 2004, 23 (03) : 311 - 317